Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
CPT-1 irreversible inhibitor
Etomoxir is an inhibitor of carnitine palmitoyltransferase A (CPT1), which is required for the oxidation of long-chain acyl CoA esters. Also a strong inhibitor of mitochondrial CPT1 and a candidate as an anti-diabetic drug.- Han-Lin Lu, .et al. , Phytother Res, 2026, Jun;40(6):3688-3703 PMID: 41947488
- Chai-Wan Kim, .et al. , bioRxiv, 2026, Jan 12:2026.01.12.698694 PMID: 41648407
- Dina Baier, .et al. , Adv Sci (Weinh), 2023, Nov;10(32):e2301939 PMID: 37752764
- Theresa Mendrina, .et al. , Pharmaceutics, 2023, Feb 16;15(2):677 PMID: 36839999
- A. Geneste, .et al. , BMC Pharmacol Toxicol, 2020, 21: 61 PMID: 32795383
-
OGT inhibitor
OSMI-4 is a low nanomolar O-GlcNAc transferase (OGT) inhibitor, with an EC50 of 3 μM in cells.- Haoxue Wang, .et al. , FASEB J, 2026, Feb 28;40(4):e71592 PMID: 41729008
-
NMPRTase Inhibitor
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.- Natsuko Kitajima, .et al. , J Cell Mol Med, 2026, May 20;30(10):e71187 PMID: 42159653
- T Nakajo, .et al. , Biochem Biophys Res Commun, 2024, Oct 30:731:150371 PMID: 39004065
- Takeshi Katayoshi, .et al. , Sci Rep, 2022, Nov 9;12(1):19040 PMID: 36352014
- Takeshi Nakamura, .et al. , Shimane Journal of Medical Science, 2022, 38 (2), 59-66
- Takeshi Katayoshi, .et al. , J Photochem Photobiol B, 2021, Jun 12;221:112238 PMID: 34130091
- Yool Lee, .et al. , Sci Adv, 2021, 7 PMID: 33579708
- Peter M LoCoco, .et al. , eLife, 2017, 6: e29626 PMID: 29125463
-
SphK2 inhibitor
ABC294640 is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity. -
MGAT3 inhibitor
PF-06471553 is a potent, selective and orally available monoacylglycerol acyltransferase 3 (MGAT3) inhibitor, with an IC50 of 92 nM. -
Thymidine phosphorylase inhibitor
Tipiralacil hydrochloride, also known as TPI, is a thymidine phosphorylase inhibitor (TPI).
-
GSTP1-1 inhibitor
Ezatiostat is a liposomal small-molecule glutathione analog inhibitor of glutathione S-transferase (GST) P1-1 with hematopoiesis-stimulating activity. -
ACAT1 Inhibitor
ATR-101 is in clinical development for the treatment of adrenocortical carcinoma (ACC). -
SPHK inhibitor
Peretinoin, also known as NIK-333 , orally available, acyclic retinoid with potential antineoplastic and chemopreventive activities. Peretinoin binds to and activates nuclear retinoic acid receptors (RAR), which in turn recruit coactivator proteins and promote, with other transcriptional complexes, the transcription of target genes. As a result, this agent may modulate the expression of genes involved in the regulation of cell proliferation, cell differentiation, and apoptosis of both normal and tumor cells. -
glutathione analog inhibitor
Ezatiostat hydrochloride (TER199;TLK199 hydrochloride) is a glutathione analog inhibitor of glutathione S-transferase P1-1 (GSTP1-1). -
GSTO1 inhibitor
GSTO1-IN-1 is a potent glutathione S-transferase omega 1 (GSTO1) inhibitor with an IC50 of 31 nM. -
MGAT2 inhibitor
MGAT2-IN-1 is an orally active inhibitor of monoacylglycerol acyltransferase (MGAT2) with IC50 of 7.8 and 2.4 nM for human and mouse MGAT2, respectively. -
ACAT inhibitor
ACAT-IN-1 cis isomer is a potent ACAT inhibitor with an IC50 of 100 nM. -
ACAT inhibitor
RP 73163 Racemate is the racemate of RP 73163. RP 73163 is a potent ACAT inhibitor, with cholesterol lowering activity. -
SphK1 Inhibitor
PF-543 Citrate is a novel cell-permeant inhibitor of SphK1 with a K(i) of 3.6 nM, PF-543 is sphingosine-competitive and is more than 100-fold selective for SphK1 over the SphK2 isoform. -
SphK2 inhibitor
K145 is a selective sphingosine kinase-2 (SphK2) inhibitor and anticancer agent. -
ACAT/SOAT inhibitor
CI 976 is a trimethoxy fatty acid anilide inhibitor of liver and intestinal acyl coenzyme A cholesterol acyltransferase (ACAT) and sterol O-acyltransferase (SOAT). Cl 976 lowers non-high density lipoprotein (non-HDL) cholesterol and increases HDL-cholesterol concentrations. -
ACAT inhibitor
Cyclandelate is an effective inhibitor of rat hepatic acycloenzyme A: cholesterol acyltransferase (ACAT) with IC50 of 80 μM. -
Ghrelin O-acyltransferase (GOAT) inhibitor
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer's disease, Parkinson's disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors. -
ACAT1 inhibitor
Nevanimibe hydrochloride (PD-132301 hydrochloride; ATR101 hydrochloride) is a selective and potent acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. -
ACAT-1 inhibitor
K-604 dihydrochloride is a potent and selective acyl-CoA:cholesterol acyltransferase 1 (ACAT-1) inhibitor with an IC50 of 0.45??0.06 μM. -
OGT inhibitor
OSMI-1 is a potent cell-permeable inhibitor of O-GlcNAc transferase (OGT), with an IC50 value of 2.7 μM. This compound effectively decreases protein O-linked N-acetylglucosamine (O-GlcNAcylation) levels in various mammalian cell lines while maintaining the integrity of cell surface N- and O-linked glycans. OSMI-1 serves as a valuable tool for studying the regulatory roles of O-GlcNAcylation in cellular processes and diseases. -
SPHK1 Inhibitor
PF-543 hydrochloride is a potent and selective inhibitor of Sphingosine Kinase 1 (SPHK1), exhibiting an IC50 of 2 nM and a Ki of 3.6 nM. It demonstrates over 100-fold selectivity for SPHK1 compared to SPHK2, making it a valuable tool for studying sphingosine-mediated signaling pathways. PF-543 hydrochloride effectively inhibits the formation of sphingosine 1-phosphate (S1P) in whole blood with an IC50 of 26.7 nM, and it has been shown to induce apoptosis, necrosis, and autophagy in various cell types, highlighting its potential in cancer and therapeutic research applications. -
SphK1 Inhibitor
SphK1-IN-2 is a selective inhibitor targeting sphingosine kinase 1 (SphK1), exhibiting an IC50 value of 19.81 nM for SphK1 while demonstrating minimal inhibition of SphK2 (IC50 > 10 μM). This compound demonstrates anti-proliferative properties, induces cell cycle arrest, and promotes apoptosis in various cancer cell lines. SphK1-IN-2 is applicable in cancer research, providing insights into the role of sphingolipid metabolism in tumor progression and potential therapeutic strategies. -
CerS1 inhibitor
P053 is a potent, non-competitive, and selective inhibitor of ceramide synthase 1 (CerS1), exhibiting an IC₅₀ of 0.5 μM. It functions as an endogenous regulator of mitochondrial fatty acid oxidation in skeletal muscle, influencing cellular energy metabolism. By modulating ceramide synthesis, P053 also acts as a systemic regulator of whole-body adiposity, making it a valuable compound for studying lipid metabolism, energy homeostasis, and metabolic disorders. -
ACAT inhibitor
Enniatin B1 is a mycotoxin produced by Fusarium species, known for its diverse bioactivities. It functions as a moderate inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), with an IC₅₀ of 73 μM in assays using rat liver microsomes, implicating a role in lipid metabolism modulation. Enniatin B1 is capable of crossing the blood-brain barrier, suggesting potential effects on central nervous system function. It also decreases the activation of ERK1/2 (p44/p42 MAPK) and moderately inhibits TNF-α-induced NF-κB activation, indicating anti-inflammatory and cell signaling modulatory properties. -
SPHK1/2/MDA Inhibitor
SKI-349 is a dual-target inhibitor of sphingosine kinase 1 and 2 (SPHK1/2) and modulates microtubule assembly (MDA). This compound exhibits significant anticancer activity, effectively reducing cell viability and invasion in liver cancer. SKI-349 also disrupts the AKT/mTOR signaling pathway, making it a valuable tool for investigating mechanisms of cancer progression and potential therapeutic strategies in oncology research. -
SphK1 Inhibitor
SphK1-IN-4 is a selective inhibitor of sphingosine kinase 1 (SphK1), an enzyme involved in sphingolipid metabolism. This compound has demonstrated potent inhibitory effects on SphK1 activity, making it a valuable tool for investigating the role of sphingosine kinase in cancer biology, particularly in lung cancer research. Its application can facilitate the exploration of therapeutic strategies targeting SphK1 in various cancer models. -
SPHK1 Inhibitor
SK1-I is a competitive inhibitor of sphingosine kinase 1 (SPHK1) with an isozyme-specific mechanism, exhibiting a Ki value of 10 μM. This compound selectively targets SPHK1 without affecting other kinases such as PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ, or CamK2β. SK1-I is noted for its ability to enhance autophagy and exhibits potential antitumor activity, making it a valuable reagent for cancer research and studies involving lipid metabolism. -
SphK inhibitor
N,N-Dimethylsphingosine is a potent inhibitor of sphingosine kinase (SphK), a key enzyme involved in sphingolipid metabolism. This compound exhibits significant biological activity by modulating sphingosine-1-phosphate levels, which can influence cell proliferation, survival, and migration. It is commonly utilized in research applications related to cancer biology, neurobiology, and inflammation studies, providing insights into the roles of sphingolipids in various pathological conditions. -
SPHK1 Inhibitor
Amgen-23 is a selective inhibitor of sphingosine kinase 1 (SPHK1), exhibiting an IC50 value of 20 nM, while demonstrating lower potency against sphingosine kinase 2 (SPHK2) with an IC50 of 1.6 µM. This compound is valuable for investigating the role of SPHK1 in cancer biology and may facilitate the development of novel anticancer therapies. Its use in research settings can enhance the understanding of sphingolipid metabolism and cellular signaling pathways in tumorigenesis. -
SphK Inhibitor
SphK1&2-IN-1 is a potent inhibitor of sphingosine kinases 1 and 2 (SphK1 and SphK2), key enzymes involved in sphingosine-1-phosphate biosynthesis. This compound exhibits thermal stability, making it suitable for various biochemical assays. SphK1&2-IN-1 is used in research applications focused on cancer, inflammation, and neurodegenerative diseases, providing valuable insights into sphingolipid signaling pathways. -
SphK2 Inhibitor
SLM6031434 hydrochloride is a selective inhibitor of sphingosine kinase 2 (SphK2), exhibiting an IC50 of 0.4 μM. This compound is known for its anti-fibrotic properties, primarily by promoting sphingosine accumulation and enhancing Smad7 expression. Research indicates that SLM6031434 effectively reduces tubulointerstitial fibrosis in a unilateral ureteral obstruction (UUO) mouse model, making it valuable for investigations into proteinuric kidney diseases and chronic kidney disease (CKD). -
SphK2 Inhibitor
SphK2-IN-1 is a selective inhibitor of sphingosine kinase 2 (SphK2), exhibiting an IC50 of 0.359 μM. This compound plays a crucial role in modulating sphingolipid metabolism, making it valuable in the study of various diseases. SphK2-IN-1 is particularly relevant for research involving cancer, inflammation, and neurological and cardiovascular disorders, providing insights into the therapeutic potential of targeting sphingosine signaling pathways.
